Stocktoria
VYNE Therapeutics Inc. VYNE
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-01-25
VYNE Therapeutics Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 | $21.0M | $443,000 | $10.6M | $4.6M | $674,000 |
| R&D expense | $19.2M | $30.9M | $16.3M | $18.4M | $19.5M | $43.5M | $51.2M | $64.5M | $29.0M | $11.3M |
| SG&A expense | — | — | — | $16.4M | $20.3M | $89.5M | $45.1M | $14.0M | — | — |
| Operating income | -$29.7M | -$43.6M | -$29.3M | -$34.3M | -$38.9M | -$252.5M | -$95.9M | -$74.9M | -$29.6M | -$14.3M |
| Interest expense | — | — | — | $0 | $5.6M | $4.4M | $921,000 | $0 | — | — |
| Income tax | $4,000 | $4,000 | $0 | $13,000 | -$448,000 | -$258,000 | -$176,000 | $212,000 | $0 | — |
| Net income | -$26.5M | -$39.8M | -$28.5M | -$23.2M | -$73.3M | -$255.6M | -$95.2M | -$74.2M | -$29.1M | -$14.1M |
| EPS (diluted) | $-0.62 | $-0.93 | $-2.78 | $-7.28 | $-25.64 | $7.88 | — | — | — | — |
| Operating cash flow | -$33.1M | -$34.0M | -$25.3M | -$29.2M | -$56.4M | -$137.1M | -$73.4M | -$68.7M | -$28.2M | -$2.3M |
| Free cash flow | — | — | — | — | -$56.4M | -$137.2M | -$74.5M | -$69.2M | -$28.2M | -$2.3M |
| Cash & equivalents | $24.0M | $19.9M | $30.6M | $30.9M | $42.2M | $57.6M | $43.8M | $27.9M | $10.2M | $4.0M |
| Inventory | — | — | — | — | $7.3M | $7.4M | $1.4M | — | — | — |
| Total assets | $30.2M | $66.9M | $97.7M | $40.8M | $67.0M | $93.7M | $81.2M | $139.9M | $66.9M | $42.1M |
| Total liabilities | $2.4M | $14.8M | $8.9M | $9.3M | $18.4M | $56.2M | $63.6M | $9.6M | $14.6M | $12.5M |
| Shareholders' equity | $27.8M | $52.1M | $88.7M | $31.2M | $48.6M | $37.5M | $17.6M | $92.2M | $68.6M | -$29.4M |
Growth · year-over-year · Revenue CAGR -1.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +13.8% | +18.2% | -11.1% | -48.8% | -95.6% | +4638.8% | -95.8% | +132.2% | +579.8% | — |
| EPS growth | — | — | — | — | -425.4% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.